Project Grant R01AI184895
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$738K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Drexel University (XF3XM9642N96)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19129, USA
Similar Awards
This $813,160 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop combination vaccines targeting multiple stages and species of the human malaria parasite. The primary focus is on creating mRNA-LNP vaccines that protect against infection by Plasmodium falciparum and P. vivax sporozoites, as well as block transmission by Plasmodium gametocytes. The research will...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,121,728 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Drexel University. The grant supports research to investigate the proton pumping mechanisms and energy metabolism of the ring stage of the malaria parasite Plasmodium falciparum, which is responsible for the majority of malaria deaths globally. The research aims to provide insights into how the metabolically quiescent...
This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year...
This federal Project Grant award of $686,895.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of next generation compounds in the ELQ series for once-monthly oral prophylaxis against malaria. The primary awardee, Oregon Health & Science University, is optimizing the structural features of the lead candidate ELQ-596 to advance a more potent and longer-acting molecule for human clinical...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the impact of microbial exposure on Plasmodium vaccine efficacy. The $205,125 award to the Hennepin Healthcare Research Institute will utilize a mouse model mimicking human immune responses to define the immune response to Plasmodium vaccination and test an IL-15 adjuvant to boost...
This federal Project Grant award of $153,512 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the Circumsporozoite Protein (CSP)-specific memory B cell pool generated during Plasmodium infection or immunization in a murine model and relevant human clinical trial samples. The research objective is to understand how previous Plasmodium infection impacts the response to subsequent vaccination, and to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $690,500 to Boston University Medical Campus to conduct research on the limited efficacy of the booster dose of the RTS,S malaria vaccine in African children. The project aims to investigate the underlying immune mechanisms responsible for the poor antibody responses to the booster dose, with the goal of informing strategies to optimize the...
This federal Project Grant award of $250,796 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Maryland, Baltimore supports planning activities for a two-part clinical trial to assess the safety, immunogenicity, and efficacy of the PfSPZ-LARC2 malaria vaccine in malaria-exposed adults and children in Burkina Faso. Key planning activities to be conducted include developing the clinical trial protocol,...
This $125,250 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to elucidate the mechanisms regulating Wolbachia bacterial infections in Anopheles mosquitoes, the vectors of human malaria. The goal is to gain insights into the cytoplasmic incompatibility induced by Wolbachia that may prevent natural infections in Anopheles, with the aim of generating tools for Wolbachia-based...
This $470,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research led by Tufts University School of Medicine to investigate mechanisms of erythrocyte adhesion in Plasmodium falciparum malaria. The research aims to elucidate how the Knob-Associated Histidine Rich Protein (KAHRP) mediates the formation of knob structures on infected red blood cells, enabling their adhesion to endothelial...